Filing identity and period
The supplied filing is Ventrus BioSciences, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2011, filed August 15, 2011. This does not match the request metadata naming Assembly Biosciences, Inc.; verify the company and filing before relying on this summary.
Business context and financial results
Ventrus was a development-stage specialty pharmaceutical company developing gastrointestinal products, including VEN 309 (iferanserin) for hemorrhoids and VEN 307 (diltiazem) for anal fissures. It had no product revenue; profitability and conventional margins were not meaningful.
| Metric | Q2 2011 | Q2 2010 | First half 2011 | First half 2010 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| R&D expense | $3.10m | $0.52m | $4.07m | $0.93m |
| G&A expense | $3.80m | $0.14m | $5.50m | $0.18m |
| Net loss | $6.96m | $2.13m | $9.68m | $4.15m |
| Basic and diluted loss per share | $0.97 | $4.76 | $1.35 | $9.27 |
| Operating cash used | — | $4.67m | $2.97m |
At June 30, cash and cash equivalents were $11.37m, total current assets $11.47m, total assets $11.52m, and total liabilities $2.09m. Current liabilities were $0.77m. The company reported no bank line or term-note balance; Paramount Credit Partners notes had $1.573m principal outstanding, shown at $1.320m net of discount, plus $0.148m interest payable. Stockholders’ equity was $9.43m. Six-month financing cash flow was $1.48m, including $2.42m net IPO over-allotment proceeds and $0.27m from warrant exercises, partly offset by repayment of bank debt. The filing reports no cash-flow margin.
Changes versus prior comparable periods
Q2 R&D increased 495% year over year, principally reflecting expanded VEN 309 development following the IPO. First-half R&D rose 335%. G&A rose sharply from limited 2010 operations; much of 2011 G&A reflected stock-based compensation and consultant stock payments. First-half employee/director stock compensation was $1.56m and consultant stock payments were $3.24m. Interest expense fell substantially after convertible notes converted to common stock in December 2010. Loss per share narrowed year over year as the weighted-average share count increased substantially following the IPO; the net loss itself increased.
Outlook, risks, and unusual items
- Management expected to incur substantial losses and higher development costs, with no product revenue anticipated for at least several years. At the time of the report, management expected cash after the July 2011 offering to fund operations into 2014; it cautioned that assumptions could prove wrong and further financing might be needed.
- VEN 309: the company planned to begin one pivotal U.S. Phase III trial in summer 2011, expected data in Q1 2012, and said an NDA could be filed as early as 2014, subject to results and other factors. VEN 307: its partner was conducting a European Phase III trial, with data expected in Q2 2012; potential U.S. trial plans and an NDA target in 2013 depended on trial results and formulation decisions.
- Estimated remaining development and acquisition-related expenditures included approximately $32m for VEN 309, $14m for VEN 307 obligations and development, and $12m to acquire iferanserin rights. These are estimates, not guaranteed costs or outcomes.
- A July 19, 2011 equity offering generated approximately $47.5m net proceeds. The company used offering proceeds to repay the $1.573m PCP principal and $0.156m accrued interest. The related-party notes carried a 10% rate and were owed to an entity whose managing member was the company’s largest stockholder.
- The iferanserin rights purchase required a $12m payment at closing, anticipated by November 15, 2011, and was subject to specified conditions, including safety-event provisions. The company had paid $0.5m on signing. License arrangements also include potential milestones and royalties; the amended VEN 307 agreement included up to $1m in patient-enrollment milestones and a $0.4m payment upon receipt of a final European study report.
- Management concluded disclosure controls were not effective at June 30, 2011 because previously identified material weaknesses persisted. Remedial steps included formalizing accounting-control policies and hiring a full-time controller.
- Cash held at financial institutions sometimes exceeded federally insured limits. Clinical development, regulatory approval, intellectual-property, financing, and execution risks could materially affect timing, costs, and commercialization.
Important facts for investors to verify
- Confirm the filing belongs to Ventrus BioSciences, not Assembly Biosciences, and verify the correct issuer and reporting period.
- Verify the closing and net proceeds of the July offering, and the repayment of PCP principal and interest.
- Check subsequent clinical-trial progress, data timing, safety disclosures, regulatory requirements, and whether the stated NDA timelines remain achievable.
- Assess the conditions and closing status of the $12m iferanserin rights acquisition and the company’s total remaining development and license obligations.
- Review remediation and testing of the material weaknesses in disclosure controls and financial reporting.
- Reconcile the filing’s operating-cash-use figure: the cash-flow statement shows $4,666,935 for the first half of 2011, while MD&A states $4,666,933.